Trials / Completed
CompletedNCT00767897
The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 72 (actual)
- Sponsor
- Indiana University · Academic / Other
- Sex
- Female
- Age
- 9 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
The proposed study is a pilot study and a first step towards developing an optimized HPV vaccination strategy for girls who have CKD, or are on dialysis or have a kidney transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Human Papillomavirus Vaccine | The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks. |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2008-10-07
- Last updated
- 2024-03-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00767897. Inclusion in this directory is not an endorsement.